Table 3 Efficacy parameters in the two groups of patients with AGA treated with “matched therapy” versus “non-matched therapy”
Matched therapy | Non-matched therapy | p valuesb | |||
|---|---|---|---|---|---|
N = 94 | N = 160 | ||||
N | % a | N | % a | ||
PFS2/PFS1 | |||||
Median (range) | 0.91 (0–14.9) | 0.67 (0–25.3) | |||
N with ratio ≥ 1.3 (95%CI) | 32 | 36% (26–47) | 26 | 20% (14–29) | 0.013 |
Missing | 5 | 33 | |||
PFS2 | |||||
Median, months (95%CI) | 2.9 (2.7–3.2) | 2.8 (2.2–3.2) | |||
Missing | 1 | 25 | |||
6-month PFS2 (95%CI) | 28% (20–39) | 16% (11–24) | 0.099 | ||
Clinical response | |||||
Complete response | 2 | 2% | 2 | 1% | 0.249 |
Partial response | 15 | 17% | 33 | 24% | |
Stable disease | 14 | 16% | 12 | 9% | |
Progressive disease (PD) | 58 | 65% | 93 | 66% | |
Disease control (DC) (95%CI) | 31 | 35% (25–46) | 47 | 34% (26–42) | 0.887 |
NA | 5 | 20 | |||
PFS2 if DC | |||||
Median, months (95%CI) | 8.5 (6.9–19.8) | 5.7 (5.4–7.3) | |||
6-month PFS2 (95%CI) | 79% (66–95) | 41% (29–58) | 1.86E−03 | ||
Missing | 0 | 3 | |||
PFS2 if PD | |||||
Median, months (95%CI) | 1.9 (1.6–2.8) | 1.9 (1.6–2.1) | |||
6-month PFS2 (95%CI) | 2% (0–12) | 1% (0–8) | 0.824 | ||
Missing | 0 | 7 | |||
OS | |||||
Median, months (95%CI) | 8.1 (6.2–12.2) | 8.9 (6.5–11.1) | |||
6-month OS (95%CI) | 62% (52–73) | 59% (51–68) | 0.791 | ||
Missing | 3 | 11 | |||